Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
Tweet Send to a Friend
Morgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $250.00 price target on Abbvie (NYSE: ABBV).The analyst comments "ABBV ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
